2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
849
Carcinoma, Non-Small-Cell Lung
551
Neoplasms
509
Prostatic Neoplasms
501
Lung Neoplasms
313
Colorectal Neoplasms
307
Multiple Myeloma
289
Neoplasm Metastasis
251
Melanoma
241
Ovarian Neoplasms
215
Leukemia, Myeloid, Acute
209
Pancreatic Neoplasms
206
Squamous Cell Carcinoma of Head and Neck
173
Carcinoma, Renal Cell
164
Stomach Neoplasms
162
Recurrence
161
Carcinoma, Hepatocellular
160
Lymphoma
156
Brain Neoplasms
151
Glioblastoma
147
Uterine Cervical Neoplasms
144
Head and Neck Neoplasms
141
Lymphoma, Non-Hodgkin
140
Triple Negative Breast Neoplasms
136
Leukemia, Lymphocytic, Chronic, B-Cell
136
Urinary Bladder Neoplasms
135
Precursor Cell Lymphoblastic Leukemia-Lymphoma
132
Colonic Neoplasms
115
Hematologic Neoplasms
114
Lymphoma, Follicular
112
Interventions
mirvetuximab soravtansine
1
liposomal doxorubicin
1
Paclitaxel
1
Gemcitabine
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
×
Clear all
NCT04274426
2026-05-13
MIROVA
AGO Research GmbH
Phase 2
Active not recruiting
136 enrolled